GLA
RYTM icon

Great Lakes Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Great Lakes Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-136,950
Closed -$7.17M – 870
2024
Q3 		$7.17M Buy
+136,950
New +$6.56M 0.06% 250

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Great Lakes Advisors's RYTM Position: Q4 2024 in Review

Great Lakes Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2024, closing a stake of 136,950 shares — an estimated $7.17M sold.

Great Lakes Advisors first reported a position in RYTM in Q3 2024 and held it in 1 quarter. The position peaked at $7.17M in Q3 2024. 203 funds tracked by Wall St. Rank hold RYTM as of Q4 2024.

  • Great Lakes Advisors reported no remaining Rhythm Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Great Lakes Advisors sold 136,950 Rhythm Pharmaceuticals shares in Q4 2024, an estimated $7.17M.
  • Great Lakes Advisors first reported a position in Rhythm Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Great Lakes Advisors's Rhythm Pharmaceuticals position peaked at $7.17M in Q3 2024.
  • 203 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2024.

Based on Great Lakes Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.